Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2014, Vol. 8 Issue (4) : 427-432     DOI: 10.1007/s11684-014-0385-4
The evolution of surgical and medical treatment of aortic root aneurysm
Xu Yu Jin1,2,*(),Li Yuan1,2,4,Mario Petrou1,John R. Pepper3,*()
1. Oxford Heart Centre, John Radcliffe Hospital, Oxford OX3 9DU, UK
2. Oxford Echo Core Lab, NDCLS, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DU, UK
3. Academic Department of Cardiac Surgery, Royal Brompton Hospital, London SW3 6NP, UK
4. Department of Ultrasonography, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
Download: PDF(488 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Since first report of aortic root replacement in 1968, the surgical risk and long term outcome of patients with aortic root aneurysm have been continuously improving. In the last 30 years, the surgical approach is also evolving towards more valve conservation with prophylactical intervention at an earlier clinical stage. Translational research has also led to emerging surgical innovation and new drug therapy. Their efficacies are currently under vigorous clinical trials and evaluations.

Keywords aortic root aneurysm      aortic root replacement      valve sparing root replacement      personalised external aortic root support     
Corresponding Authors: Xu Yu Jin   
Online First Date: 01 December 2014    Issue Date: 18 December 2014
URL:     OR
Fig.1  Illustration of aortic full root replacement.
Fig.2  Illustration of valve sparing aortic root replacement by Yacoub Remodelling or David Reimplantation.
Fig.3  Illustration of aortic full root replacement.
1 Olsson C, Thelin S, St?hle E, Ekbom A, Granath F. Thoracic aortic aneurysm and dissection: increasing prevalence and improved outcomes reported in a nationwide population-based study of more than 14,000 cases from 1987 to 2002. Circulation2006; 114(24): 2611–2618
doi: 10.1161/CIRCULATIONAHA.106.630400 pmid: 17145990
2 Howard DP, Banerjee A, Fairhead JF, Perkins J, Silver LE, Rothwell PM; Oxford Vascular Study. Population-based study of incidence and outcome of acute aortic dissection and premorbid risk factor control: 10-year results from the Oxford Vascular Study. Circulation2013; 127(20): 2031–2037
doi: 10.1161/CIRCULATIONAHA.112.000483 pmid: 23599348
3 Jeremy RW, Huang H, Hwa J, McCarron H, Hughes CF, Richards JG. Relation between age, arterial distensibility, and aortic dilatation in the Marfan syndrome. Am J Cardiol1994; 74(4): 369–373
doi: 10.1016/0002-9149(94)90405-7 pmid: 8059700
4 Murdoch JL, Walker BA, Halpern BL, Kuzma JW, McKusick VA. Life expectancy and causes of death in the Marfan syndrome. N Engl J Med1972; 286(15): 804–808
doi: 10.1056/NEJM197204132861502 pmid: 5011789
5 Cooley DA, Bloodwell RD, Beall AC Jr, Hallman GL, De Bakey ME. Surgical management of aneurysms of the ascending aorta. Including those associated with aortic valvular incompetence. Surg Clin North Am1966; 46(4): 1033–1044
pmid: 6003089
6 Bentall H, De Bono A. A technique for complete replacement of the ascending aorta. Thorax1968; 23(4): 338–339
doi: 10.1136/thx.23.4.338 pmid: 5664694
7 Isselbacher EM. Thoracic and abdominal aortic aneurysms. Circulation2005; 111(6): 816–828
doi: 10.1161/01.CIR.0000154569.08857.7A pmid: 15710776
8 Pepper J, Golesworthy T, Utley M, Chan J, Ganeshalingam S, Lamperth M, Mohiaddin R, Treasure T. Manufacturing and placing a bespoke support for the Marfan aortic root: description of the method and technical results and status at one year for the first ten patients. Interact Cardiovasc Thorac Surg2010; 10(3): 360–365
doi: 10.1510/icvts.2009.220319 pmid: 20007995
9 Murgatroyd F, Child A, Poloniecki J, Treasure T, Pumphrey C. Does routine echocardiographic measurement of the aortic root diameter predict the risk of aortic dissection in the Marfan syndrome. European Heart Journal1991; 12(abstract supplement): 410
10 Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L, Wenink A;Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J2007; 28(2): 230–268
pmid: 17259184
11 Benedetto U, Melina G, Takkenberg JJ, Roscitano A, Angeloni E, Sinatra R. Surgical management of aortic root disease in Marfan syndrome: a systematic review and meta-analysis. Heart2011; 97(12): 955–958
doi: 10.1136/hrt.2010.210286 pmid: 21228428
12 Gott VL, Greene PS, Alejo DE, Cameron DE, Naftel DC, Miller DC, Gillinov AM, Laschinger JC, Pyeritz RE. Replacement of the aortic root in patients with Marfan’s syndrome. N Engl J Med1999; 340(17): 1307–1313
doi: 10.1056/NEJM199904293401702 pmid: 10219065
13 Gott VL, Cameron DE, Alejo DE, Greene PS, Shake JG, Caparrelli DJ, Dietz HC. Aortic root replacement in 271 Marfan patients: a 24-year experience. Ann Thorac Surg2002; 73(2): 438–443
doi: 10.1016/S0003-4975(01)03336-7 pmid: 11845856
14 Kim SY, Martin N, Hsia EC, Pyeritz RE, Albert DA. Management of aortic disease in Marfan syndrome: a decision analysis. Arch Intern Med2005; 165(7): 749–755
doi: 10.1001/archinte.165.7.749 pmid: 15824293
15 Yacoub MH, Gehle P, Chandrasekaran V, Birks EJ, Child A, Radley-Smith R. Late results of a valve-preserving operation in patients with aneurysms of the ascending aorta and root. J Thorac Cardiovasc Surg1998; 115(5): 1080–1090
doi: 10.1016/S0022-5223(98)70408-8 pmid: 9605078
16 David TE, Armstrong S, Ivanov J, Feindel CM, Omran A, Webb G. Results of aortic valve-sparing operations. J Thorac Cardiovasc Surg2001; 122(1): 39–46
doi: 10.1067/mtc.2001.112935 pmid: 11436035
17 Westaby S, Saito S, Anastasiadis K, Moorjani N, Jin XY. Aortic root remodeling in atheromatous aneurysms: the role of selected sinus repair. Eur J Cardiothorac Surg2002; 21(3): 459–464
doi: 10.1016/S1010-7940(01)01155-1 pmid: 11888763
18 Komiya T, Tamura N, Sakaguchi G, Kobayashi T. Modified partial aortic root remodeling in acute type A aortic dissection. Interact Cardiovasc Thorac Surg2009; 8(3): 306–309
doi: 10.1510/icvts.2008.190223 pmid: 19064582
19 Charitos EI, Stierle U, Sievers HH, Misfeld M. Valve-sparing aortic root remodeling with partial preservation of the intact native aortic sinuses. Eur J Cardiothorac Surg2009; 36(3): 589–591
doi: 10.1016/j.ejcts.2009.05.036 pmid: 19616961
20 Treasure T, Crowe S, Chan KM, Ranasinghe A, Attia R, Lees B, Utley M, Golesworthy T, Pepper J. A method for early evaluation of a recently introduced technology by deriving a comparative group from existing clinical data: a case study in external support of the Marfan aortic root. BMJ Open2012; 2(2): e000725
doi: 10.1136/bmjopen-2011-000725 pmid: 22389361
21 Treasure T, Takkenberg JJ, Golesworthy T, Rega F, Petrou M, Rosendahl U, Mohiaddin R, Rubens M, Thornton W, Lees B, Pepper J. Personalised external aortic root support (PEARS) in Marfan syndrome: analysis of 1-9?year outcomes by intention-to-treat in a cohort of the first 30 consecutive patients to receive a novel tissue and valve-conserving procedure, compared with the published results of aortic root replacement. Heart2014; 100(12): 969–975
doi: 10.1136/heartjnl-2013-304913 pmid: 24395977
22 Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan’s syndrome. N Engl J Med1994; 330(19): 1335–1341
doi: 10.1056/NEJM199405123301902 pmid: 8152445
23 Silverman DI, Burton KJ, Gray J, Bosner MS, Kouchoukos NT, Roman MJ, Boxer M, Devereux RB, Tsipouras P. Life expectancy in the Marfan syndrome. Am J Cardiol1995; 75(2): 157–160
doi: 10.1016/S0002-9149(00)80066-1 pmid: 7810492
24 Collod-Béroud G, Le Bourdelles S, Ades L, Ala-Kokko L, Booms P, Boxer M, Child A, Comeglio P, De Paepe A, Hyland JC, Holman K, Kaitila I, Loeys B, Matyas G, Nuytinck L, Peltonen L, Rantamaki T, Robinson P, Steinmann B, Junien C, Béroud C, Boileau C. Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database. Hum Mutat2003; 22(3): 199–208
doi: 10.1002/humu.10249 pmid: 12938084
25 Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet2003; 33(3): 407–411
doi: 10.1038/ng1116 pmid: 12598898
26 Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science2006; 312(5770): 117–121
doi: 10.1126/science.1124287 pmid: 16601194
27 Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC 3rd. Angiotensin II blockade and aortic-root dilation in Marfan’s syndrome. N Engl J Med2008; 358(26): 2787–2795
doi: 10.1056/NEJMoa0706585 pmid: 18579813
28 Groenink M, den Hartog AW, Franken R, Radonic T, de Waard V, Timmermans J, Scholte AJ, van den Berg MP, Spijkerboer AM, Marquering HA, Zwinderman AH, Mulder BJ. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J2013; 34(45): 3491–3500
doi: 10.1093/eurheartj/eht334 pmid: 23999449
29 Mullen MJ, Flather MD, Jin XY, Newman WG, Erdem G, Gaze D, Valencia O, Banya W, Foley CE, Child A. A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol. Trials2013; 14(1): 408
doi: 10.1186/1745-6215-14-408 pmid: 24289736
30 Lacro RV, Dietz HC, Wruck LM, Bradley TJ, Colan SD, Devereux RB, Klein GL, Li JS, Minich LL, Paridon SM, Pearson GD, Printz BF, Pyeritz RE, Radojewski E, Roman MJ, Saul JP, Stylianou MP, Mahony L; Pediatric Heart Network Investigators<?Pub Caret?>. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J2007; 154(4): 624–631
doi: 10.1016/j.ahj.2007.06.024 pmid: 17892982
31 Lacro RV, Guey LT, Dietz HC, Pearson GD, Yetman AT, Gelb BD, Loeys BL, Benson DW, Bradley TJ, De Backer J, Forbus GA, Klein GL, Lai WW, Levine JC, Lewin MB, Markham LW, Paridon SM, Pierpont ME, Radojewski E, Selamet Tierney ES, Sharkey AM, Wechsler SB, Mahony L; Pediatric Heart Network Investigators.Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy. Am Heart J2013; 165(5): 828–835, e3
doi: 10.1016/j.ahj.2013.02.019 pmid: 23622922
No related articles found!
Full text